CHMP recommends Provenge ( Dendreon) for treatment of Prostate Cancer
Dendreon Corporation announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has on 28 June 2013 adopted a positive opinion recommending that Provenge(autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or Sipuleucel-T) be granted marketing authorization in the European Union (EU), for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant Prostate Cancer in male adults in whom chemotherapy is not yet clinically indicated. The CHMP's recommendation follows a positive recommendation by the Committee for Advanced Therapy (CAT).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins